Stockwinners Market Radar for January 10, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:16 EST ITC rules Apple violated trade laws by infringing on Masimo patent - The company states: "A United States Administrative Law Judge in Washington, D.C. ruled that Apple (AAPL) violated Section 337 of the Tariff Act of 1930 as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of Masimo's (MASI) pulse oximeter patents. Apple first released its pulse oximeter sensor with the Apple Watch Series 6 in 2020 and continues to use it in the current Apple Watches. The United States International Trade Commission will now consider whether to implement an import ban on these Apple Watches."

20:02 EST Cathie Wood's ARK Investment bought 33.8K shares of Coinbase today

18:54 EST WWE board elects Vince McMahon Executive Chairman of the Board - The company states: "WWE announced that its Board of Directors unanimously elected Vince McMahon Executive Chairman of the Board. Stephanie McMahon has resigned from her roles as Chairwoman and Co-CEO. Nick Khan will serve as WWE CEO."

18:43 EST Werewolf Therapeutics jumps 12% as RA Capital raises stake - Shares of Werewolf Therapeutics are up 12% afterhours at $2.50 per share. In a 13D/A filing, RA Capital has disclosed that it is raising its stake in the stock to 18.0% from 14.6%, also stating: "In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer, members of the board of directors of the Issuer, and/or or other third parties, to discuss matters regarding the Issuer, including but not limited to its operations, strategic direction, governance or capitalization, and potential business combinations or dispositions involving the Issuer or certain of its businesses. Dr. Derek DiRocco, a Partner of RA Capital, currently serves as a director of the Issuer and therefore will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director."

18:31 EST Eisai submits MAA for lecanemab to EMA - Eisai (ESALY) and Biogen (BIIB) announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer's disease to the European Medicines Agency. This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study, which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD and is subject to a validation to determine whether the EMA accepts the application for review.

18:01 EST Broadwind announces $175M wind tower order with global turbine manufacturer - Broadwind announced receipt of approximately $175M in new tower orders from a leading global wind turbine manufacturer. Fulfillment of the new order will occur during the full year 2023 and conclude by the end 2024. Ordered tower sections will be produced at both the company's Abilene and Manitowoc facilities. "This transformational new tower order is an historic accomplishment for our entire team, one that further establishes Broadwind as the leading precision manufacturer of heavy fabrications advancing the global energy transition," stated Eric Blashford, President and CEO of Broadwind. "This important win will support a balanced production schedule over the next two years, materially increase system-wide facility utilization, and drive improved economies of scale across our organization."

17:54 EST Keurig Dr Pepper CEO sells $4.5M in common stock - In a regulatory filing, Keurig Dr Pepper disclosed that its CEO Robert Gamgort sold 125K shares of common stock on January 6th in a total transaction size of $4.5M.

17:52 EST Urban Edge announces record leasing activity in 2022 - Urban Edge Properties "announced that it achieved record volume for new leases signed during 2022. The Company leased over 1 million square feet, up from a previous record of 683,000 square feet, through the execution of 69 new leases. Same-property leased occupancy increased to 95.4% at year-end, a 110 basis point increase compared to December 31, 2021. During the fourth quarter, the company executed 53 new leases, renewals, and options totaling 788,000 square feet. Same-space leases totaled 564,000 square feet and generated an average spread of 31% on a cash basis. During the year, the company executed 159 new leases, renewals, and options totaling over 2 million square feet. Same-space leases totaled 1.8 million square feet and generated an average spread of 12% on a cash basis."

17:20 EST Halozyme announces anticipated key events in 2023 - Anticipated 2023 Key Events: Projected growth of greater than20% in the company's high-margin, recurring revenue stream from royalties to approximately $445 to $455 million driven by continued strength in Wave 2 products, including DARZALEX and Phesgo utilizing ENHANZE technology, as well as full year auto-injector royalty contribution. Two ENHANZE subcutaneous approvals and commercial launches by collaboration partners, including SC efgartigimod and SC atezolizumab. Four Phase 3 study data readouts from products utilizing ENHANZE by the company's collaboration partners: SC efgartigimod in CIDP, ITP and Pemphigus; SC ocrelizumab for certain patients with multiple sclerosis. At least 2 new products utilizing ENHANZE entering Phase 1 development by the company's collaboration partners. At least one new collaboration and licensing agreement for ENHANZE, for a partner to test our developmental large volume auto-injector plus ENHANZE(R), and for our small volume auto-injector. Initiation of a clinical study to continue to evaluate the feasibility testing of our large volume auto-injector. Up to $150 million in share repurchases, dependent on market conditions and other factors, as part of the $750 million three-year share repurchase plan authorized by Halozyme's board of directors in December 2021 demonstrating the company's continued commitment to a balanced capital allocation strategy.

17:12 EST AMTD Digital gets confirmation of key officers not selling shares before 2024 - AMTD Digita "announced today that it has received further confirmation of the previously announced undertakings from the relevant parties that AMTD Group, Dr. Calvin Choi, AMTD IDEA Group and the executive officers of AMTD Digital will not sell any shares they own in AMTD Digital in the open market before August 2024. AMTD Digital initially announced its knowledge of these commitments on August 16, 2022."

17:01 EST AIG CFO Shane Fitzsimons to take temporary medical leave of absence - AIG "announced that Shane Fitzsimons, Executive Vice President and CFO, AIG, will take a temporary medical leave of absence, effective immediately. Mark Lyons, who previously served as AIG's Chief Financial Officer, has been appointed Interim CFO in addition to his role as Executive Vice President, Global Chief Actuary and Head of Portfolio Management."

16:45 EST Ichor Holdings falls 16% after below-consensus Q4 and Q1 pre-announcement

16:33 EST Integra LifeSciences reiterates plans to initiate $150M share buyback in 2023 - The company is reiterating its plans to initiate a $150M share repurchase in 2023. The company may repurchase shares at its discretion, subject to applicable regulatory and other legal requirements. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions, regulatory requirements, and other corporate considerations, and could be suspended or discontinued at any time as determined by management. Commencement of share repurchases is expected to occur in early 2023, and the Company may utilize various methods to make the repurchases.

16:21 EST Conn's extending gains afterhours on WSJ report of acquisition interest, up 13% - Shares of Conn's are extending their gains in the afterhours session, rising another 13% to $11.36 after finishing regular trading up 15% on late-day report from The Wall Street Journal that Franchise Group is eyeing a potential deal for the company.

16:18 EST Myomo to cut roughly 12% of its workforce - Myomo announced a reduction in force for the purpose of improving operating efficiency in its direct billing channel and reduce its cash burn. The action today involved the elimination of approximately 12% of its workforce, impacting employees in its call center and administrative functions. This action and other cost reductions being undertaken by the company are expected to save in excess of $2M on an annual basis. "While unfortunate, this action was necessary in improve operating leverage and extend our cash runway as we continue to work on obtaining coverage and reimbursement for the MyoPro for Medicare Part B patients," said Paul Gudonis, Myomo's Chairman and Chief Executive Officer.

16:17 EST Cohen & Steers reports preliminary AUM $80.4B as of December 31, 2022 - A decrease of $3.8B from assets under management at November 30, 2022. The decrease was due to market depreciation of $2.6B, distributions of $887M and net outflows of $260M.

16:16 EST TechnipFMC awarded 'significant' contract by Wintershall Dea - TechnipFMC announces that it was "awarded a significant engineering, procurement, construction, and installation contract by Wintershall Dea Norge AS for its Dvalin North project. The contract covers the design, engineering, manufacture, and installation of pipe for the Dvalin North field, which will be tied back to the Heidrun Platform via the existing Dvalin field on the Norwegian Continental Shelf. For TechnipFMC, a "significant" contract is between $75 million and $250 million. This award was included in inbound orders in the fourth quarter of 2022."

16:15 EST ProKidney publishes trial design for trial of REACT for diabetes related to CKD - ProKidney announced the publication of the trial design and early data analysis from REGEN-003, a Phase 2 clinical study of Renal Autologous Cell Therapy, in the Journal of Blood Purification. The paper, titled Renal Autologous Cell Therapy, REACT, in Type 2 Diabetes with Late Stage 4 Diabetes-Related Chronic Kidney Disease: Trial Design and Early Analysis, was published online and will appear later this year in the print edition of the Journal. "In this study, we believe we have demonstrated the potential of REACT to delay the need for dialysis in patients with late CKD Stage 4 diabetic kidney disease, DKD,," said Joseph Stavas, M.D., ProKidney's SVP, Head of Global Clinical Development, and lead author of the manuscript. "This is a high-risk patient population with seriously reduced kidney function. Stavas further commented, "The goal of REACT is to halt the progression of CKD and preserve kidney function in patients who would otherwise experience kidney failure and progress to dialysis. We believe that REACT has the potential to have a significant, positive impact on patients' health and quality of life. Publication of the 003-study design and results in this prestigious journal provides important recognition of the benefit REACT could have in the lives of these very sick patients."

16:12 EST Glaukos announces clinical updates for several corneal disorders - Glaukos "announced positive clinical updates for several of its Corneal Health pipeline programs, including the commencement of subject enrollment in a second Phase 3 confirmatory trial for Epioxa, and promising initial results from the company's Phase 2a clinical trial for GLK-301. Glaukos commenced subject enrollment in its second Phase 3 confirmatory pivotal trial for Epioxa, its next-generation corneal cross-linking therapy for the treatment of keratoconus. Glaukos plans to randomize approximately 290 subjects in this trial and is targeting enrollment completion by the end of 2023. As a reminder, the FDA has confirmed Glaukos' first Phase 3 pivotal trial for Epioxa, which met the pre-specified primary efficacy endpoint, would be adequate to support the submission and review of an eventual New Drug Application, in conjunction with this second trial. As Glaukos continues to advance its clinical plans for Epioxa, it remains well-positioned to serve keratoconus patients with its first-generation corneal cross-linking therapy, Photrexa(R), or Epi-off(TM), which remains the only FDA-approved treatment shown to slow and halt the progression of keratoconus."

16:11 EST PDF Solutions and proteanTecs team on semiconductor analytics - PDF Solutions and proteanTecs, a deep data analytics firm, announced a collaboration on combined semiconductor analytics solutions intended to provide deeper insights on yield, quality and reliability by integrating proteanTecs deep agent and analytics solutions with the Exensio Platform. PDF Solutions and proteanTecs bring to the collaboration complementary expertise and market knowledge that combines PDF Solutions' process characterization and semiconductor big data analytics solutions, with proteanTecs' deep data offering for chip and system lifecycle analytics.The semiconductor industry is poised to grow in the next decade to become a trillion-dollar industry by 2030. About 70-percent of this growth is anticipated to be driven by three industries: automotive, computation and data storage, and wireless. These markets rely on high performance electronics with uncompromised lifetime functionality, leading semiconductor companies to seek advanced approaches for characterization, volume production and in-field monitoring. Through this collaboration, proteanTecs and PDF Solutions intend to offer combined solutions that leverage each company's strengths, to enable data-driven insights and visibility in all stages of manufacturing.

16:09 EST Luokung Technology receives non-compliance letter from Nasdaq - Luokung Technology announced that on January 4 the Company received notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that, based upon the Company's non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550 as of January 3 the Company's securities would be delisted from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by Nasdaq at least pending the hearing and the expiration of any extension that may be granted by the Panel following the hearing. There can be no assurance however that the Panel will grant the Company's request for continued listing or that the Company will be able to evidence compliance with the Rule and all other applicable criteria for continued listing on Nasdaq within the period of time that may be granted by the Panel.

16:07 EST First Financial appoints Michelle Hickox as CFO - First Financial Bankshares announced the election of Michelle S. Hickox as Executive Vice President and CFO to replace James R. Gordon.Hickox most recently served as CFO of Independent Financial Group, and its subsidiary, Independent Bank, an $18B publicly-traded bank holding company based in McKinney, Texas, where she led IBTX through its initial public offering in 2013 and played a key role in ten acquisitions during her tenure. Prior to joining IBTX, Hickox was an audit partner at RSM US LLP in Dallas, serving financial institutions throughout Texas. She is a certified public accountant and a graduate of Texas A&M University, where she currently serves as a trustee of the 12th Man Foundation. Gordon resigned from his position as Executive Vice President and CFO, secretary and treasurer of the Company and its affiliates and subsidiaries effective January 9, 2023, in order to pursue other opportunities. Gordon's resignation did not result from any disagreement with the Company, and Gordon has agreed to serve as a consultant to assist in the transition process.

16:06 EST Blend Labs announces new initiatives, will cut 28% of onshore employee base - Blend announced series of specific initiatives that support its previously communicated plan to accelerate its path to profitability. The initiatives announced today aim to right-size the Company's cost structure, focus its investments on the highest potential growth opportunities, and realign its leadership to drive the Company's transition from a product company to a platform company. Specifically, they include: A 28% reduction in Blend's onshore employee base impacting Blend Title and corporate operations in R&D, sales and marketing and general and administrative functions. This latest reduction in force and prior savings initiatives are expected to reduce Blend's annualized cost of revenue and operating expenses by over $100 million in the aggregate on a non-GAAP basis exiting calendar 2023 relative to the third quarter of 2022; Implementation of planned enhancements to Blend's go-to-market and investment strategies designed to enhance the Company's product suite, revenue models and gross margins, including: Allocating an increased portion of operating expenses into Blend Builder, the Company's configurable software platform, which carries a subscription fee on top of success based transaction fees. This platform is already the foundation of Blend's non-mortgage offerings, and over time will give mortgage lenders the flexibility and power they need to differentiate from their competitors; d for Blend's large mortgage customer base, focusing on helping lenders be even more efficient by implementing the large backlog of features built over the past several years, including Loan Officer Toolkit, Self-serve Prequalification, Blend Income, and Blend Close; The appointment of Amir Jafari as Head of Finance & Administration, a new position that will oversee Finance, People Operations, Legal, Compliance, IT and Information Security. As part of this transition, Blend President Tim Mayopoulos will leave his management role in the first quarter, while remaining a member of the Board of Directors; Head of Finance Marc Greenberg will depart Blend after a transition period that includes the filing of the Company's Form 10-K with the SEC in March 2023; and Head of Legal, Compliance, and Risk Crystal Sumner will depart Blend in early February. Upon Sumner's departure, Winnie Ling, who currently leads the Company's corporate and securities legal functions, will become Head of Legal, reporting to Jafari. "Over recent months we have undertaken ambitious financial and strategic planning to align our cost structure, innovation spend and go-to-market focus with both current market realities and how our customers most want to leverage our platform," said Nima Ghamsari, Head of Blend. "Today we're announcing a comprehensive set of initiatives that affirms and accelerates our previously communicated path to profitability, including enabling Blend to realize enhanced gross margins from our Blend Platform offerings, including mortgage banking, beginning as soon as the second half of 2023."

16:03 EST ViaSat receives certificate in China to install connectivity in Boeing aircrafts - Viasat (SAT) announced it has been awarded a Civil Aviation Administration of China, or CAAC, Validation of Supplemental Type Certificate, or VSTC, to install its advanced Ka-band satellite connectivity system on the Boeing (BA) 737 aircraft series. Following the validation of the A320 series in April 2022, this latest approval for the 737-NG series further strengthens the foundation for Chinese airlines to install and deploy Viasat's industry-leading In-Flight Connectivity, or IFC, system, including antenna, radome, modem, server and WAPs. The Boeing 737 series VSTC joins a portfolio of Viasat certifications that have been applied globally to install Viasat's IFC system on nearly 2,000 commercial aircraft. In total, Viasat currently serves 18 airline customers, averaging over 200,000 flights per month around the world. Announced in December 2022, Sichuan Airlines is China's first domestic carrier to partner with Viasat's In-Flight Connectivity Solution and China Satcom's Satellite System. Sichuan Airlines has multiple aircraft delivering the service currently.

16:00 EST Conn's trading resumes

15:38 EST Group One Trading reports 13.49% stake in MicroStrategy - In a regulatory filing, it was reported that Group One Trading beneficially owns 1,261,744 shares of MicroStrategy, representing a 13.49% stake.

14:34 EST Alaska Air plans to hire more than 3,500 workers this year - Alaska Airlines announced plans to hire more than 3,500 new employees this year in a variety of roles and functions. "From maintenance technicians to contact center agents, flight attendants to pilots, customer service agents to software engineers, we will have jobs available for anyone who wants to be part of our team," the company said. "Most of the new jobs are based at our hubs in Seattle and Portland, as well as locations up and down the West Coast. Benefits like the ability to work from home and flexibility of schedules are also available with some roles. Many of the positions do not require previous airline experience, so it's the perfect time to try a new career. The openings will be posted at careers.alaskaair.com throughout the year."

14:01 EST Lakeland Financial increases dividend 15% to 46c per share - Lakeland Financial, parent company of Lake City Bank, announced that the board of directors approved a quarterly cash dividend for the first quarter of 2023 of 46c per share, payable February 6 to shareholders of record as of January 25. The quarterly dividend represents a 15% increase over the quarterly dividend rate of 40c per share paid in 2022. "We are pleased to announce another healthy increase to our dividend rate. Our consistent long-term operating performance and a strong capital foundation provide the capacity to comfortably increase dividends to shareholders," commented David Findlay, President and CEO.

13:12 EST iSpecimen names Tracy Curley as CEO - iSpecimen announced that its board of directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately. Curley was previously appointed Interim CEO in September 2022, while concurrently serving as the company's CFO. With the appointment of Curley as CEO, the board will be initiating a comprehensive search process to identify a new CFO, iSpecimen said.

12:54 EST Boeing reports 774 commercial orders in 2022 - Boeing reported 774 commercial orders last year after cancellations and conversions, including 561 orders for the 737 family and 213 orders for the company's twin-aisle airplanes. Boeing delivered 69 commercial jets in December, including 53 737 MAX, bringing total deliveries for 2022 to 480 airplanes. "We worked hard in 2022 to stabilize 737 production, resume 787 deliveries, launch the 777-8 Freighter and, most importantly, meet our customer commitments," said Boeing Commercial Airplanes President and CEO Stan Deal. "As the airline industry expands its recovery, we are seeing strong demand across our product family, particularly the highly efficient 737 MAX and the 787 Dreamliner. We will stay focused on driving stability within our operations and the supply chain as we work to deliver for our customers in 2023 and beyond." Commercial orders after cancellations and conversions include: 561 orders for the 737 MAX, adding new customers such as ANA, Delta Air Lines, IAG, and low-cost carrier Arajet; 213 orders for widebodies, including 114 787s, 31 767s and 68 777s; 78 orders across Boeing's freighter line, including 45 orders for the 767-300 Freighter and current 777 Freighter; Launching the 777-8 Freighter with more than 50 orders, including conversions. Commercial deliveries include: 387 737s, including 374 737 MAX and 13 military-derivative airplanes; 93 widebodies, including 5 747s, 33 767s, 24 777s and 31 787s; 44 new production freighters; As of Dec. 31, 2022, the Commercial Airplanes backlog is 4,578 jets.

12:34 EST Four Seasons Edu (Cayman) Inc ADR trading resumes

12:13 EST Senator Sanders says Moderna COVID vaccine pricing shows 'unacceptable' greed - Senator Bernie Sanders of Vermont tweeted: "I sent a letter today to the CEO of Moderna with a simple message: In the midst of a public health crisis, quadrupling the price of a publicly-funded COVID-19 vaccine is unacceptable corporate greed." Reference Link

12:00 EST Wallbox falls -11.1% - Wallbox is down -11.1%, or -51c to $4.03.

12:00 EST Rayonier Advanced Materials falls -28.3% - Rayonier Advanced Materials is down -28.3%, or -$2.59 to $6.57.

12:00 EST Frontline rises 24.7% - Frontline is up 24.7%, or $2.79 to $14.12.

11:58 EST Cosmos Holdings updates agreement to acquire Cana Laboratories - Cosmos Health has extended and updated its previously issued binding letter of intent to acquire Pharmaceutical Laboratories CANA, a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by global pharmaceutical and healthcare companies. Cosmos Health has renegotiated the acquisition price of Cana to achieve much improved payment terms. The updated letter of intent will remain effective until May 31, 2023.

11:51 EST CVS Health saw flu vaccinations 'elevate a little bit' in latter part of 2022

11:24 EST Globant acquires Vertic, terms not disclosed - Globant has acquired Vertic, a Copenhagen and New York based creative consultancy with a strong focus on life-sciences and other B2B disciplines. This acquisition will allow Globant to consolidate its global digital marketing network and start operations in Denmark from where it will offer services to companies based in the Nordic countries.

11:23 EST Boeing announces total Q4 deliveries 152 aircraft - Total 2022 deliveries were 480 aircraft, Boeing said in a statement.

11:01 EST Boeing delivered 110 737s in Q4, 2 747s - Boeing delivered 12 767s in Q4, as well as six 777s and 22 787s.

11:01 EST Relativity Acquisition Corp trading resumes

10:40 EST Global Tech Industries executes binding LOI for Creatd acquisition - Global Tech Industries Group (GTII) announced that they have executed a binding Letter of Intent regarding the acquisition of Creatd (CRTD) by GTII for $100 million of GTII restricted shares of common stock. Final acquisition terms will be subject to due diligence, regulatory approval, and approval of the boards and shareholders of both parties. As part of the LOI, Creatd has committed to a 30- day halt to any discussions with other potential acquirers. As due diligence and negotiations continue, Creatd intends to complete the spinoff of its media subsidiary, OG Collection Inc.

10:16 EST Silo Pharma advances clinical study on effects of psilocybin in inflammation - Silo Pharma announced a progress update on its sponsored research study with the University of California, San Francisco examining psilocybin's effect on inflammatory activity in humans. The clinical study evaluates three populations of patients suffering from Parkinson's disease, bipolar disorder, and chronic pain. Eric Weisblum, CEO of Silo Pharma, commented, "The UCSF research team is making progress on the clinical trial. The data gathered from these studies could uncover the role of inflammatory activity on such conditions as Parkinson's, Bipolar disorder and Chronic Pain. Utilizing Psilocybin in this study in a regimented dosing pattern, we hope to gain significant data both in mechanism of action and potential biomarker for personalization of psilocybin therapy. The targeted patient populations from the study could provide support for the development and use of psilocybin as a therapeutic coupled with our novel homing peptides and topical technology." For each patient population, the clinical studies involve preparation therapy, two separate dosing sessions with psilocybin, and integration therapy. At the Clinical & Translational Science Institute at UCSF, four blood samples are collected from each participant, one at baseline before treatment begins, one at 24 hours post dosing for each dosing session, and one at a 30-day follow up. The research team is on track to complete data collection from Parkinson's disease patients by the end of February 2023. Data collection is expected to begin in early 2023 for the bipolar study, and in April 2023 for the chronic pain study patients.

10:05 EST Cinedigm, TripleLift partner for in-show advertising - TripleLift announced it has partnered with Cinedigm to launch In-Show advertising for brands and advertisers across its flagship streaming service, Cineverse, and suite of FAST channels, including The Bob Ross Channel, Realmadrid TV, The Dove Channel and more.

10:02 EST TPG launches inaugural TPG NEXT Fund - TPG announced the launch of the inaugural TPG NEXT fund, which will back the next generation of underrepresented alternative asset managers. CalPERS will anchor the fund with a $500 million commitment, and TPG will continue to raise third-party capital to address its significant pipeline and compelling opportunity set across the diverse manager landscape. The target size of the fund was not disclosed.

10:00 EST Euronav NV falls -18.0% - Euronav NV is down -18.0%, or -$2.87 to $13.07.

10:00 EST Bloom Energy rises 9.2% - Bloom Energy is up 9.2%, or $1.83 to $21.72.

10:00 EST Oak Street Health rises 27.6% - Oak Street Health is up 27.6%, or $6.22 to $28.80.

09:47 EST Rayonier Advanced Materials falls -11.6% - Rayonier Advanced Materials is down -11.6%, or -$1.06 to $8.10.

09:47 EST Stem rises 9.1% - Stem is up 9.1%, or 74c to $8.88.

09:47 EST Oak Street Health rises 31.8% - Oak Street Health is up 31.8%, or $7.18 to $29.75.

09:40 EST ImmuCell trading resumes

09:35 EST Cartesian Growth Corp trading resumes

09:30 EST Cartesian Growth Corp trading halted, volatility trading pause

09:30 EST FPCM to join Focus partner firm GYL Financial Synergies - Focus Financial Partners entered into a definitive agreement under which Financial Partners Capital Management will join Focus partner firm GYL Financial Synergies, GYL is headquartered in West Hartford, CT and has offices in Westport, CT and Parsippany, NJ. The transaction is expected to close in the first quarter of 2023, subject to customary closing conditions. Founded in 1988, FPCM is a full-service registered investment advisor headquartered in New York, NY. The firm provides comprehensive financial planning and investment management services to high net worth individuals and families. FPCM is currently led by the firm's three partners, Aaron Cohen, Vincent Marsden and Craig Giventer, supported by their experienced team of financial advisors and client support service professionals. Through this transaction, GYL will establish a presence in the New York City wealth management market, allowing it to extend its regional presence in the Northeast. The GYL team will also benefit from the addition of a strong team of advisors with deep, long standing client relationships. Once the transaction closes, GYL's institutional and private client services in West Hartford, Westport, Parsippany, and New York City will move forward together under one brand name, GYL Financial Synergies.

09:28 EST Eastern Company appoints Mark Hernandez as CEO - The Eastern Company announced that its Board of Directors has named Mark Hernandez, currently a member of the Board of Directors, the Company's next Chief Executive Officer, effective January 23, 2023. Mr. Hernandez will succeed August Vlak, who has served as CEO since 2016. Mr. Hernandez has led Navistar's global manufacturing, supply chain, and logistics since 2018, most recently as Executive Vice President.

09:25 EST Jaguar Health, Filament Health form joint venture Magdalena Biosciences - Jaguar Health, Filament Health and One Small Planet announced the formation of a U.S.-based joint venture named Magdalena Biosciences, Inc. to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder in adults. Initial funding of US$1,000,000 will be invested by Boulder, Colorado-based One Small Planet, founded by Will Peterffy. This funding will be payable in quarterly installments in 2023 based on the achievement of defined milestones by Magdalena Biosciences. The goal of the collaboration is to extend the botanical drug development capabilities of Jaguar and Filament in order to develop pharmaceutical-grade, standardized drug candidates for mental health disorders, and to partner with a potential future licensee to develop and commercialize these novel plant-based drugs.

09:24 EST Jupiter Wellness commences trading on Upstream - Jupiter Wellness will become available at 10:00am EST under the ticker symbol JUPW on Upstream. The Jupiter Wellness digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "JUPW".

09:23 EST Informatica announces CFO transition - Informatica announced the appointment of Michael McLaughlin, a seasoned finance leader and most recently Chief Financial Officer of FICO, as Informatica's Executive Vice President and Chief Financial Officer effective January 16, 2023. McLaughlin succeeds Eric Brown, who has notified the Informatica Board of Directors of his intention to step down to pursue other opportunities. Brown's departure follows more than four years as Informatica's Chief Financial Officer. Brown will remain a consultant to the company through March 31, 2023, to support a seamless transition.

09:22 EST Jamf Holding helps 71,000 customers succeed with Apple - Jamf announced that as of December 31, 2022, it is now helping approximately 71,000 active customers succeed with Apple and is running on approximately 30 million devices worldwide.

09:21 EST Clover Health CEO says 2023 will be 'pivotal year' - "2023 will be a pivotal year for Clover Health and I believe we will prove out the strength of our approach to managing care for Medicare beneficiaries. It's an exciting time for me to transition into the role of Chief Executive Officer, working with our team to deliver results for our members, our physician network partners, and our shareholders", said Andrew Toy, Chief Executive Officer of Clover Health. "We expect to build upon our positive momentum from 2022 to deliver continued improvement in our financial performance across both our Insurance and Non-Insurance lines. During the most recent Medicare Advantage Annual Enrollment Period, we intentionally priced our Insurance plans with profitability in mind as opposed to growth. Due to this strategic shift, we expect to start 2023 with Insurance membership approximately in line with our Insurance membership as of January 1, 2022, and we expect favorability in 2023 MCR and growth in 2023 Insurance top-line revenue. On our Non-Insurance business, we are continuing with our previously disclosed strategic shift to reduce the number of participant providers we accept into the program in connection with an increased prioritization of profitability. The resulting improvement in the returning member mix for both lines of business is expected to further improve our financial profile. We intend to issue additional guidance for full-year 2023 at a later date. However, the partial guidance for full-year 2023 we are issuing today highlights the anticipated favorable impact of our ongoing strategy to prioritize profitability", said Mr. Toy.

09:21 EST Wejo enters into business combination with TKB Critical Technologies 1 - Wejo Group (WEJO) announced that it has entered into a definitive business combination agreement to combine with TKB Critical Technologies 1 (USCT). The proposed business combination is subject to a number of closing conditions and the parties anticipate that the transaction will close in the second quarter of 2023. Upon closing of the business combination, the combined company will retain Wejo's ticker symbol and will continue to trade on the Nasdaq Stock Market. Through a combination of an anticipated PIPE raise and funds from TKB's trust, Wejo believes that this transaction can raise up to $100M to fund its growth initiatives and position the company to execute on its strategic goals, and potentially reach cash flow breakeven which is expected by mid-2025. Wejo will continue to work on additional short-term funding initiatives to provide bridge capital until the transaction closes. The proposed business combination is structured as a stock-for-stock merger, whereby each of Wejo and TKB will become wholly owned subsidiaries of a new holding company. At closing of the transaction, each issued and outstanding share and warrant of TKB will be exchanged for the right to receive a number of Wejo Holdings common shares and warrants, respectively, based on an exchange ratio calculated by dividing $11.25 by the volume weighted average price per Wejo common share for the 15 consecutive trading days immediately preceding the second trading day prior to the date of Wejo's shareholders' meeting, subject to a collar. Wejo shareholders will receive equivalent shares in Wejo Holdings. The structure of this transaction seeks to limit TKB stockholder redemptions and maximize cash delivered to Wejo by providing TKB investors with an approximately 10% premium to the estimated cash in TKB's trust in Wejo Holdings shares. The transaction is expected to provide up to $100 million in combined cash proceeds from the funds in trust and the proceeds of a contemplated PIPE to be raised prior to closing to successfully execute on Wejo's strategy. The board of directors of Wejo and the board of directors of TKB have each unanimously approved the business combination agreement and the transactions contemplated thereby. Richard Barlow, co-founder and CEO of Wejo, said "This transaction is transformative for Wejo, providing significant funding progress in our bridge to profitability and allowing us to make critical investments in our technology platform and product portfolio. The deal signifies a clear recognition that Wejo's market differentiating Smart Mobility for Good products and services are world-class and positions the company to invest and capitalize on the expected tidal wave of business growth opportunities."

09:19 EST Ahold Delhaize CFO Natalie Knight to depart - Ahold Delhaize announces that Natalie Knight, CFO since 2020, has informed the company that she will pursue another career opportunity in the United States of America, and will leave Ahold Delhaize. A six months' notice period applies. The search for a successor has started.

09:18 EST Trupanion CEO to assume additional role as chair of the board - Trupanion announced that Darryl Rawlings, Founder & Chief Executive Officer, will assume the additional role of Chair of the Board, effective immediately. Murray Low, PhD, the prior Chair of the Board, will assume the role of Lead Independent Director. Today's announcement is in alignment with the Company's long-term succession plans and Mr. Rawlings's intention to support a smooth CEO succession in 2025 and, if amenable to shareholders, to serve as Chair of the Board until 2035.

09:17 EST Rev Group publishes 2022 Corporate Sustainability Report - REV Group has released its 2022 Corporate Sustainability Report. The report shares the company's progress and continued commitment across Environmental, Social and Corporate Governance, ESG, priorities. "We began our sustainability journey in 2019 with our first report, and now four years later, we've made improvements and are advancing on the road ahead," said Rod Rushing, President and CEO of REV Group. "We are committed to improving the quality of life for our customers and communities by fulfilling our priorities as an industry leader and champion of sustainability and safety."

09:15 EST MCI Capital announces results of cash tender offer for shares of StarTek - MCI Capital announced the final results of its previously announced cash tender offer to purchase up to 4,000,000 shares of common stock of StarTek at a purchase price of $4.20 per share, which expired at 5:00 p.m., New York City time, on January 4, 2023. The tender offer fully closed on January 9th, 2023. MCI has accepted for payment, at a purchase price of $4.20 per share, and promptly paid $12,350,713.20 for, all 2,940,646 shares of common stock that were validly tendered and not validly withdrawn pursuant to the Offer. After giving effect to this transaction, MCI and its affiliates beneficially own approximately ~7.3% of StarTek's outstanding shares of common stock as of October 31, 2022.

09:13 EST IonQ acquires assets of Entangled Networks - IonQ "announced its acquisition of the operating assets of Entangled Networks, a Toronto-based company focused on enabling computation across multiple distributed quantum processors. As part of the transaction, the Entangled Networks team will join IonQ to launch IonQ Canada, strengthening IonQ's already growing international presence. Entangled Networks, previously funded by investors like OurCrowd, marks IonQ's first corporate acquisition, demonstrating ongoing market and industry leadership."

09:13 EST Qualigen Therapeutics receives orphan drug designation for QN-302 - Qualigen announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead drug candidate, QN-302, for the indication of Pancreatic Cancer. QN-302 is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

09:12 EST Royal Gold provides update on Q4 2022 stream segment sales - Royal Gold announced that its wholly owned subsidiary, RGLD Gold AG, sold approximately 63,100 gold equivalent ounces comprised of approximately 46,000 gold ounces, 706,600 silver ounces and 2,000 tonnes of copper related to its streaming agreements during the three-month period ended December 31, 2022. The Company had approximately 21,000 ounces of gold, 461,200 ounces of silver and 400 tonnes of copper in inventory at December 31, 2022. RGLD Gold AG's average realized gold, silver and copper prices for the fourth quarter were $1,710 per ounce, $20.09 per ounce and $8,004 per tonne, respectively. Cost of sales was approximately $396 per GEO for the fourth quarter.

09:12 EST Total Energy announces preliminary 2023 capex budget of $51.7M - Total Energy Services announces its preliminary 2023 capital expenditure budget of $51.7 million which includes $25.6 million of expansion capital and $26.1 million for equipment maintenance and recertifications. The 2023 expansion capital budget includes $18.4 million for rig upgrades in the Contract Drilling Services and Well Servicing segments. These upgrades include the modification of an idle drilling rig for deployment to Australia in the first quarter of 2024 under a three year contract and the modification of an idle service rig for deployment in Canadian thermal oil operations in late 2023. In addition, $5.0 million of expansion capital will be deployed for continued growth of the North American compression rental business and $2.2 million for new rental equipment for the Rentals and Transportation Services segment. The $26.1 million capital maintenance budget will be directed towards equipment re-certifications and maintenance in all business segments, including $4.1 million for new drilling rig tubulars. Total intends to finance its preliminary 2023 capital expenditure budget with cash on hand and cash flow from operations.

09:10 EST Revelation Biosciences announces mandatory unit separation on January 13 - Revelation Biosciences announced that, on January 13, 2023, the Company's units, which trade with the ticker symbol "REVBU" will be mandatorily separated and the units will no longer trade on the Nasdaq Capital Market. Each unit is comprised of one share of the Company's common stock and one warrant that entitles the holder to purchase one share of common stock at price of $11.50 per share. In the separation, unit owners will receive the number of shares of common stock and warrants underlying such units. This is a mandatory and automatic separation, and no action is required by the holders of units. The common stock and warrants are listed on the Nasdaq Capital Market and trade with the ticker symbols "REVB" and "REVBW", respectively.

09:08 EST SourceKnowledge integrates with BigCommerce - SourceKnowledge announced a new partner integration with BigCommerce. This SourceKnowledge integration for BigCommerce saves merchants time and development resources by automatically completing the required steps to easily advertise with SourceKnowledge. This integration makes it seamless for a BigCommerce merchant to connect SourceKnowledge to their storefront, empowering them to instantly create ads based on the existing catalog and extend the reach of campaigns beyond the walled gardens of Google, Facebook and Amazon. Once installed, the BigCommerce merchant's website will automatically be tagged with the SourceKnowledge pixel to serve ads to the store's visitors.

09:05 EST Spruce Point issues 'Strong Sell' opinion on Super Micro Computer - Spruce Point issued a "Strong Sell" opinion on Super Micro Computer, saying in a research note that it believes believe investors are chasing Super Micro's "outlandish long-term revenue goals that ultimately won't convert to cash flow" while signs of financial troubles and new financial reporting pressures emerge. The firm estimates approximately 40%-50% downside risk.

09:03 EST Matterport appoints Natalie Lamb as MD, EMEA - Matterport announced the appointment of Natalie Lamb as Managing Director of EMEA, effective immediately. In this role, Lamb will be responsible for overseeing Matterport's strategic growth in enterprise and SMB segments and expanding Matterport's strategic partnerships in EMEA. She led the EMEA and APAC businesses for a privately-backed IBM startup, before most recently serving as chief commercial officer for a B2B SaaS Accounting vendor.

09:01 EST Intapp, ComplySci partner for conflict clearance operations - Intapp announced a new partnership with ComplySci. Intapp and ComplySci's partnership will deliver an integrated and comprehensive firm and personal conflicts clearance solution to clients.

08:56 EST Duos Railcar Inspection Portal technology performs over 7M scans in 2022 - Duos Technologies Group has reported that in 2022 the Company's Railcar Inspection Portal technology performed over seven million comprehensive railcar scans, of which more than 573,000 were unique railcars. This metric encompasses all railcars scanned at locations across the U.S., Canada, and Mexico, representing approximately 35% of the total freight car population in North America. Duos was also recently awarded a contract for two high-speed systems which are expected to be operational in mid-2023 in the northeast U.S. as part of a major passenger rail infrastructure upgrade. The Super RIPs will deploy new machine vision technologies capable of capturing safety data at speeds of up to 125 miles per hour. Duos expects to deploy new wheel and brake inspection technologies with this installation. The Company also recently disclosed that it intends to build and deploy additional systems around the network which can be accessed via subscription, lowering the barriers to entry for acquiring a RIP system for railroads and railcar owners alike.

08:54 EST Amdocs, Macau's CTM collaborate on commercial 5G services - Amdocs announced that CTM has 5G services in the region, supporting both non-standalone and standalone standards to bring the benefits of 5G to the residents and tourists visiting Macau. CTM commissioned Amdocs to modify its online charging and billing infrastructure to support 5G standards, enabling the operator to rapidly launch new 5G products with innovative price plans and bundling offers for prepaid and postpaid customers.

08:53 EST Bed Bath & Beyond says identified additional $80M-$100M saving opportunity - Says initiated incremental cost reductions of approximately $80M to $100M across corporate, including overhead expense and headcount. Says additional $80M to $100M savings opportunity identified across supply chain. Says on track to deliver approximately $250M of SG&A savings versus last year for the second half of FY22, or $500M on an annualized basis Says on track to complete approximately 150 store closures by the end of FY22. Comments taken from Q3 earnings conference call.

08:53 EST Orbit International reports consolidated bookings in excess of $10.2M for Q4 - Orbit International announced that consolidated bookings for the fourth quarter of 2022 were in excess of $10,200,000. Deliveries for some of these orders have already commenced during the quarter and are expected to continue through the first quarter of 2024. Mitchell Binder, President and CEO of Orbit International commented, "We are pleased to report that our consolidated bookings for the fourth quarter of 2022 exceeded $10,200,000. This solid booking quarter was primarily a result of our previously announced strong consolidated bookings for the months of October and November 2022, which totaled approximately $8,700,000. Rounding out the final month of the quarter, bookings were highlighted by over $500,000 in orders from each of our Orbit Instrument Division and Behlman Electronics Inc. subsidiary." Binder added, "We are very encouraged by the firm bookings from our OPG in the second half of 2022. OPG bookings for the month of December were highlighted by several orders for power supplies utilizing our VPX technology. Since 2016, our VPX business has steadily been increasing and increased approximately 8% in 2022 over the prior year despite a very significant order which has been delayed until 2023. In addition to the increase in bookings in 2022, we supplied new and existing customers many new prototype power supplies which historically have often evolved into new production orders with follow-on opportunities. Consequently, we believe our OPG is extremely well situated in the VPX marketplace, and we expect this business to be the foundation of future revenue growth for this segment of our business."

08:51 EST BTCS announces private beta release of StakeSeeker platform - BTCS announced the private beta launch of its proprietary Digital Asset Analytic and Staking-as-a-Service Platform: StakeSeeker. The company said, "In conjunction with the roll out of StakeSeeker, we are also pleased to announce the launch of our new investors relations and corporate website which includes a new investor presentation and provides a comprehensive resource for current and potential shareholders to gain a deeper understanding of our business and future growth prospects."

08:49 EST ExlService announces partnership with Brown & Brown Absence Services Group - EXL announced a partnership with Brown & Brown Absence Services Group. Together, the two companies will develop an end-to-end claims management service that leverages conversational AI and powerful analytics to improve the claims adjudication process. This new capability will enable extracting and analyzing critical insights from unstructured claims data to instantly tag simple claims for immediate, automated processing and send more complex cases to highly skilled specialists for detailed review informed by years of claims experience. "This new technology optimizes AI and advanced analytics to improve the speed and accuracy of claims processing, while also including humans in the loop to focus on more complex cases," said Andy Logani, senior vice president, Head of Life & Annuity Business at EXL. "This is the future of the insurance industry - we've now reached a point where AI technology is able to augment human workflows to dramatically increase the speed, accuracy and depth of analyses required to meet the demands of the current marketplace."

08:49 EST Iteris awarded $2.8M contract from SBCTA to support I-10 express lanes - Iteris announced that it has been awarded a $2.8M contract from the San Bernardino County Transportation Authority SBCTA to support the development of the I-10 Express Lanes. The project proposes to widen the I-10 highway for a stretch of 11 miles between the I-10/I-15 interchange and Pepper Street. One express lane will be added in each direction as well as new auxiliary lanes, and additional California Highway Patrol enforcement areas.

08:48 EST Runway Growth Finance completes 12 investments in Q4 - Runway Growth Finance (RWAY) provided an operational and portfolio update for the fourth quarter ended December 31, 2022. "Runway Growth capitalized on its strong momentum in the venture lending space, completing twelve investments in new and existing portfolio companies, and delivering record fourth quarter and full year originations," said David Spreng, Founder and CEO of Runway Growth. "Our team's disciplined execution in constructing a high-quality portfolio with industry-leading credit quality has Runway Growth well positioned for the year ahead regardless of market conditions. We continue to focus on deploying leverage to enhance long-term shareholder value, embracing companies that seek venture debt to generate growth. Despite a challenging macroeconomic backdrop, our team remains confident in its weather-proof platform and committed to delivering flexible financing solutions to high-quality, innovative companies." Runway Growth's net originations totaled $222.6 million in the fourth quarter. In the fourth quarter of 2022, Runway Growth funded 12 investments: six investments in new portfolio companies, and six new investments in existing portfolio companies. During the fourth quarter ended December 31, 2022, Runway Growth experienced one liquidity event totaling $10 million. In conjunction with its refinancing and upsize, an existing portfolio company prepaid its outstanding principal balance of $10 million. Subsequent to December 31, 2022, Runway Growth experienced an additional liquidity event totaling $10 million. In conjunction with a loan amendment to TRACON Pharmaceuticals, Inc. ("TCON) finalized on December 22, 2022, Tracon repaid its senior secured term loan of $10 million on January 3, 2023.

08:46 EST Journey Medical completes enrollment in Phase 3 trials of DFD-29 - Journey Medical announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 for the treatment of papulopustular rosacea. The Phase 3 clinical trials are part of a collaboration with Dr. Reddy's Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program. The DFD-29 Phase 3 clinical program consists of two multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, MVOR-01 and MVOR-02, that are expected to support an NDA submission in the United States and potentially a Marketing Authorization Application in Europe. The combined enrollment target of 640 total adult patients with moderate to severe PPR was achieved in the trials; one trial was enrolling patients in the United States, and the other was enrolling patients in both the United States and Europe. The MVOR-01 and MVOR-02 clinical trials are randomized in a 3:3:2 ratio to DFD-29, Oracea or placebo once daily for 16 weeks. The primary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to placebo for the treatment of PPR. The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea. To date, no major safety issues have been reported, and no drug-related serious adverse events have been observed. Data published in The Journal of Clinical and Aesthetic Dermatology determined DFD-29 40 mg demonstrated significantly greater efficacy than doxycycline 40 mg, placebo and DFD-29 20 mg for the treatment of PPR in a Phase 2 clinical study. DFD-29 40 mg demonstrated statistical significance compared to both placebo and doxycycline 40 mg on both co-primary endpoints-proportion of subjects with IGA treatment success and total inflammatory lesion count reduction from baseline to week 16.

08:43 EST Grom Social Enterprises issues letter to shareholders - Grom Social Enterprises issued a letter to shareholders from Darren Marks, its Chairman and Chief Executive Officer. "Fiscal 2022 was a foundational year for Grom as we fortified our core businesses to drive growth and future profitability. We remained steadfast to our values and primary objectives to provide safe, secure platforms and environments for kids to interact and explore; to deliver world class animation services; and to bring fun, novel, and authentic kids & family entertainment properties to life... We believe the social media landscape is undergoing a massive shift driven by consumer sentiment, and is now accelerating due to action taken by the Federal Trade Commission. Policy changes will soon create a lasting impact on our industry with an emerging opportunity for our Company. United States Senators Richard Blumenthal (D-CT) and Marsha Blackburn (R-TN) introduced the Kids Online Safety Act, which is comprehensive bipartisan legislation to enhance children's safety online. While major technology companies continue to grapple with the growing concern around the safety and security of their platforms, especially when it comes to children, we remain focused on building a solution that families can trust. Grom is well-positioned to reap the benefits of the growing trend of online child safety in the social media industry. We believe that Grom is the only fully Children's Online Privacy Protection Act compliant social media application in the marketplace. This designation has always been of utmost importance to us; however, it will soon become invaluable... Initiatives for 2023 and Beyond, Our existing businesses and partnerships are primed for the next phase of growth in the markets in which we operate. As we look ahead to this year, we will continue to evaluate synergistic opportunities to augment our suite of offerings and advance our primary initiatives. We are working to rebrand and relaunch the Grom mobile app, with a focus on improving the in-app user experience, and have identified unique features to develop and implement in 2023... Additionally, we will look to expand our Santa.com franchise through the broadening of our ecommerce platform and the development of original stories and content... Moreover, we will continue to expand and develop our original content and franchise property portfolio... What's more, we plan to further capitalize on commercial, licensing, and partnership opportunities for revenue growth... Finally, we intend to vertically integrate pre- and post-production services into our animation operations by either acquisition or partnership... We are expanding our commitment to the capital markets and our shareholders through enhanced investor relations initiatives to increase market awareness of our successes."

08:42 EST CVS Health sees FY23 MA membership growth in LSD-MSD range - CVS expects its total Medicare Advantage membership growth to be in the low to mid-single digit percentage range in 2023. During the annual enrollment period for 2023, CVS said its Individual MA enrollment came in below expectations, "while we are growing strongly in the dual eligible special needs market and our Group MA product continues to resonate in the market place." CVS added: "For 2023, we expanded our individual public health insurance exchange footprint to 12 states, covering approximately 40% of all addressable lives. This expansion, combined with overall market growth and several market exits by competitors, has allowed us to add more than 700,000 new members through open enrollment this year, exceeding our expectations and bringing our total exchange membership to over 750,000."

08:41 EST CVS Health repurchased 15M shares during Q4 at average share price of $99.99 - The company also entered into a $2B fixed dollar accelerated share repurchase transaction, which became effective on January 3, 2023.

08:40 EST Greystone Housing Impact announces sales of Vantage at Stone Creek, Coventry - Greystone Housing Impact Investors announced that on January 5, 2023, Vantage at Stone Creek and Vantage at Coventry, each being a 294-unit market rate multifamily property located in Omaha, NE, were sold at the direction of the respective managing members. The Partnership's investment in Vantage at Stone Creek was originated in March 2018 and the Partnership contributed equity totaling $7.1 million during construction. The Partnership's investment in Vantage at Coventry was originated in September 2018 and the Partnership contributed equity totaling $8.1 million during construction. As a result of the sales, the Partnership's equity investment in each property was redeemed. At closing of the sales, the Partnership received net cash of approximately $27.7 million, inclusive of the return of its contributed equity. The Partnership estimates it will recognize the following in the first quarter of 2023: Gains on sale totaling approximately $15.2 million, before settlement of final proceeds and expenses, Investment income totaling approximately $244,000, Net income of approximately $0.51 per Beneficial Unit Certificate, basic and diluted, based on the number of BUCs outstanding on the date of sale, and Cash Available for Distribution of approximately $0.51 per BUC, basic and diluted, based on the number of BUCs outstanding on the date of sale.

08:38 EST BioSig executes agreement with Bellin for acquisition of PURE EP technology - BioSig Technologies announced that Bellin Health System in Green Bay, Wisconsin has signed an agreement to acquire the Company's PURE EP System. The agreement follows a 60-day formal evaluation of the PURE EP System at Bellin Health. The hospital reported that the PURE EP demonstrated a significant cost savings per case as well as a substantial reduction in noise and signal interference compared to the use of conventional systems only. The agreement grants Bellin Health full autonomy with respect to its operation of the PURE EP System, and BioSig will not be required to provide an on-site clinical account manager following the new system install. "Bellin has observed, first-hand, that clear cardiac signals provide more information that can impact procedural efficiency without driving up procedural costs," commented Gray Fleming, Chief Commercial Officer, BioSig Technologies. "The terms of this agreement represent a new milestone for the PURE EP(TM) System-expanding the accessibility and automaticity of our novel digital signal processing technology."

08:38 EST Evofem: Phexxi added to Costco Member Prescription Program - Evofem Biosciences (EVFM) announced that Phexxi has been added to the Costco (COST) Member Prescription Program, giving millions of additional women access to this innovative hormone-free contraceptive. The Costco Member Prescription Program is a prescription drug discount card program that provides eligible Costco members and their eligible dependents the ability to obtain lower prices on Phexxi and other participating drugs at participating pharmacies. Costco members who are uninsured and want to pay cash for their Phexxi prescription, or who have been denied coverage by their insurer, may use this program to fill their Phexxi prescriptions for less than the typical cash pay cost.

08:35 EST Poet Technologies announces production release of optical engines - POET Technologies announced that it has released to production four optical engines, an achievement that advances the Company's commercialization goals. The small form factor optical engines with integrated directly modulated lasers, optical multiplexer, high-speed photodiodes and optical demultiplexer enable low power, cost-efficient and highly scalable 100G CWDM4, 200G FR4 and 400G FR4 pluggable transceivers for telecom and data center markets.

08:32 EST Everi Holdings' anti-laundering technology selected by British Columbia lottery - Everi Holdings was selected by the British Columbia Lottery Corporation to provide its Everi Compliance Anti-Money Laundering solution in support of BCLC's gaming and online operations. The Company will support BCLC as it conducts and manages lottery, casino, bingo, and online gaming on behalf of the province for the benefit of British Columbians. Everi also supplies land-based and online slot content throughout British Columbia.

08:30 EST Brightcove, Magnite team to boost advertising monetization for CTV, OLV - Brightcove (BCOV) announced it has entered into a strategic relationship with Magnite (MGNI). Magnite will power advertising for any Brightcove customer, growing fill and delivery to increase customer revenue. Brightcove will also integrate the SpringServe ad server to provide publishers with greater control, insight, and transparency into available ad supply. With thousands of customers globally, Brightcove has always supported standards-based integrations with ad servers and Supply-Side Platforms . After analyzing data from billions of ad-supported play requests on its leading Server Side Ad Insertion solution, Brightcove saw a significant opportunity to better help customers monetize their unsold ad opportunities. Available directly through Brightcove, Magnite's SSP capabilities will enable Brightcove to deliver revenue for these customers. Integrating with the SpringServe ad server will give those customers a transparent view of available ad inventory and a strategic opportunity to better monetize their video content. "The needs of our large, global customer base are constantly evolving, and we are committed to evolving our solutions for them, including supporting our customers' efforts to monetize their video content," said Marc DeBevoise, CEO of Brightcove. "This integration with Magnite and SpringServe is a key step to enabling us to provide our customers with best-in-class solutions to meet their needs, allowing them to increase their ad fill rate and generate better CPMs."

08:28 EST Biomerica appoints Lacy to Scientific Advisory Board - Biomerica appointed prominent physician and key opinion leader Brian Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods Technology platform, beginning with the InFoods IBS product.

08:25 EST Solid Biosciences outlines strategic priorities for 2023 - Solid Biosciences outlined its strategic priorities for 2023. Highlights from the presentation to be given at the J.P. Morgan Healthcare Conference include: Solid's corporate vision to build an innovation platform enabling the discovery and development of high-value genetic medicines for neuromuscular and cardiac diseases by integrating internal capabilities. Solid remains focused on developing next-generation AAV capsid libraries with two strategies designed to enhance cardiac and skeletal muscle tropism: AAV-SLB101 has demonstrated more than double the transduction and expression in skeletal and cardiac muscle and half reduction in expression in the liver compared with AAV9 in non-human primate studies; SGT-003 has been well tolerated across multiple animal models and experience to date supports robust and scalable manufacturability currently up to 1000L. Friedrich's Ataxia program focused on drug candidate selection and initiation of IND enabling studies: AVB-202 will be designed to express functional FXN protein; NHP studies conducted with AVB-202 manufactured using an HSV-based manufacturing method demonstrated that administration of AVB-202 led to FXN expression to significant levels in all tissues evaluated. In preclinical studies, AVB-202 resulted in safe levels of human FXN at or near physiologic levels in the NHP heart. BAG3-mediated Dilated Cardiomyopathy AVB-401 program overview: Clear mechanistic rationale between genetic BAG3 insufficiency and myofilament damage, poor contraction and heart failure; Treating BAG3-mediated DCM requires expression of functional BAG3 within heart muscle only; Solid's construct candidates utilize the AAVrh74 capsid and cardiac specific promoter; In early nonclinical studies, the specific capsid and cardiac-specific promoter combination increased cardiac expression while reducing expression in the liver; Solid is conducting additional studies to evaluate the potential of using AAV-SLB101 to develop a genetic medicine for BAG3-mediated DCM. Upcoming anticipated milestones: Report functional data from IGNITE DMD in early 2023; Submit SGT-003 IND in the second half of 2023; Initiate SGT-003 patient dosing in late 2023

08:23 EST Sharps Technology to introduce specialized refillable syringe systems in 2023 - Sharps Technology announces the advancement of the Company's specialized prefillable syringe, PFS, system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina. Sharps' specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment. Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+ million units, with additional capacities that can be scaled by 2025 with an additional 100 million units annually. Products will be manufactured utilizing state-of-the-art Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Robert Hayes, Sharps Chief Executive Officer, commented: "Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opportunity to advance our product and manufacturing strategy to include high value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond. The launch of these products could not come at a better time to support a market that is in demand for products produced in the USA that provide specialized solutions for customers that need optionality for their drug filling operations. We look forward to providing updates as we commence manufacturing in South Carolina and introduce our new products to the market."

08:20 EST Neuronetics settles litigation against Brainsway - Neuronetics (STIM) announced that it has settled the litigation filed in the District of Delaware against BrainsWay (BWAY) and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law. Under the terms of the settlement, BrainsWay agreed to stop the use of the efficacy data for the treatment of anxious depression with NeuroStar Advanced Therapy for Mental Health that was at issue in the Complaint filed by Neuronetics. The parties have agreed to keep the additional terms of the settlement agreement confidential.

08:18 EST Bionano Genomics announces 2023 Symposium - Bionano Genomics, announced its 2023 Symposium, which is the quintessential event for the optical genome mapping community to present its progress to the world. It will feature four consecutive days of OGM presentations delivered by 25 different customers worldwide across a wide range of genetic diseases, cancer and cell bioprocessing applications. The Symposium will take place virtually from January 23 to 26, 2023. During these four days, customers will showcase their latest research findings using OGM in constitutional, hematologic malignancies, and solid tumor applications. Each day will feature oral customer presentations, a live panel with Q&A and a wide range of scientific posters within the virtual exhibition hall. "At Bionano, we are working to transform the way the world sees the genome," said Erik Holmlin, PhD, president and chief executive officer of Bionano. "Symposium is our platform for the community of OGM users to describe its utility and how it can be integrated with other genome analysis tools to reveal more answers for genetic disease and cancer research applications. What impresses me most about the lineup for 2023 is the sheer breadth of topics, ranging from neural tube defects in prenatal testing to homologous recombination deficiency analysis in breast cancer and drug development with cell bioprocessing QC."

08:17 EST Safeguard Scientifics completes $3M share repurchase program - Safeguard Scientifics announced the completion of the $3 million share repurchase program announced in March 2022. As a result of this plan, the Company repurchased an aggregate of 736,577 shares for an average price of $4.09 per share. During the year ended December 31, 2022, the Company repurchased 711,481 shares for an average price of $4.13 per share utilizing $2.9 million of the authorization. The remainder of the shares were repurchased in January 2023. The Plan was operated in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended. These repurchases used existing funds and were made in open market or privately negotiated transactions. Additionally, the Company ended December 31, 2022 with $19.3 million of cash, cash equivalents, restricted cash and marketable securities. Safeguard's deployments for the year ended December 31, 2022 totaled $5.7 million, as compared to the full year 2022 deployments estimate of $5 million to $9 million previously disclosed.

08:15 EST Constellium signs multi-year agreement to supply Daher - Constellium announced that it has entered into a multi-year contract with Daher to supply a wide range of flat-rolled aluminium products, particularly for the TBM and Kodiak aircraft. With this new agreement, Constellium expands its customer portfolio for business and regional jets and becomes the strategic aluminium supplier for Daher. Under this new contract, Constellium and Daher will cooperate on joint supply chain initiatives and product development. Constellium will support TBM and Kodiak aircraft development as their production rate is increasing and will collaborate with Daher on the design of new solutions to further lightweight aircraft along with respective sustainability commitments.

08:14 EST Brainsway resolves Neuronetics litigation - BrainsWay (BWAY) reported that it has settled litigation filed by Neuronetics (STIM) in the District of Delaware. BrainsWay had filed a motion to dismiss the case, and, while that motion was pending, agreed to settle the case on mutually agreeable terms and without any admission of liability or wrongdoing, including the release of certain potential counterclaims, to avoid the time, expense and uncertainty of litigation. "We are pleased to have resolved this litigation so that we can focus our full attention on our technology and bringing our Deep TMS therapy to patients," said Christopher von Jako, P.h.D., President and CEO of BrainsWay. Except as set forth in this press release, and a corresponding announcement from Neuronetics, the parties have agreed to keep the terms of the settlement agreement confidential.

08:13 EST BioAtla provides clinical program updates, 2023 milestones - BioAtla announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones. Company updates and 2023 milestones will be presented in a fireside chat at 41st Annual J.P. Morgan Healthcare Conference, January 10, 2023. Clinical Program Updates: Phase 2 Trial of Mecbotamab Vedotin in Patients with: AXL-positive NSCLC: Part 1 of the trial ongoing in patients who have previously experienced failure of PD-1/L1, EGFR, or ALK inhibitor therapy; 29 patients enrolled to date; 20 efficacy-evaluable patients; In the non-squamous group, 10 of 18 had monotherapy and 8 of 18 had combination therapy with nivolumab; All CR / PRs observed were in the non-squamous group; 4 PRs were in the monotherapy group; 4 PRs were in the monotherapy PD-1 failure group; 1 CR in combination therapy; Following BA3011 in both monotherapy and in combination with nivolumab in advanced NSCLC patients, the safety profile continues to be differentiated, with no new safety signals observed/ AXL-positive Soft Tissue and Primary Bone Sarcomas: Following FDA feedback to the proposed Phase 2 part 2 of the potentially registrational sarcoma study, protocol for UPS study design, including primary endpoint and size of study, finalized and the study is being initiated; Part 1 of the Phase 2 study: Study is progressing with continued efficacy in UPS with 50.0% PFS at 12 weeks; Study ongoing in patients with liposarcoma, synovial sarcoma, and osteosarcoma with continued, encouraging PFS at 12 weeks; Liposarcoma - 66.7% PFS; Synovial sarcoma - 53.5% PFS; Osteosarcoma - 66.7% PFS; In refractory sarcomas, BA3011 in both monotherapy and in combination with nivolumab is generally well-tolerated with no new safety signals observed. Phase 1/2 Dose-Escalation Trial of CAB-CTLA-4 Across Multiple Solid Tumor Types responsive to CTLA-4: Trial ongoing with two of three cohorts completed without any DLTs or SAEs reported. Expected Timing for Key 2023 Milestones - 1H23: Phase 2 study of mecbotamab vedotin in patients with AXL-positive NSCLC; Initiating preparations for discussions with the FDA regarding the potentially registrational part 2 of the study in AXL-positive NSCLC patients; Submission of Phase 2 part 1 interim data for presentation at ASCO; First patient dosed in Phase 2 part 2 study in AXL-positive UPS patients; Interim data in the Phase 2 part 1 ROR-2 positive NSCLC study; CAB-EpCAM x CAB-CD3 TCE Phase 1 study initiation. 2H23: Phase 2 part 2 of the BA3011 study in NSCLC patients anticipated initiation; Interim data in the Phase 2 part 1 ROR-2 positive melanoma study; Interim data in the Phase 2 part 1 ROR-2 positive SCCHN study; Phase 1 data and Phase 2 initiation in CAB-CTLA-4 study.

08:12 EST Clean Earth's Lancaster, Texas facility earns RIOS, R2v3 certifications - Clean Earth announces its Lancaster, Texas, facility earned the RIOS and R2v3 certifications, marking the Company's fifth certified electronic recycling facility along with sites in Allentown, Pennsylvania, Modesto, California, West Melbourne, Florida, and Richmond, Virginia. The certifications are the result of extensive third-party audits ensuring that the facility and employees are capable of handling and managing e-waste.

08:10 EST TD Synnex announces $1B share repurchase pact - The TD SYNNEX board of directors has approved a share repurchase program of up to $1B of its common stock over a period of up to three years, replacing the previous three-year program. Stock repurchases may be made at management's discretion from time to time through open market or privately negotiated transactions, including pursuant to one or more Rule 10b5-1 trading plans adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

08:09 EST Ansys, RTI partner for development of mission-critical distributed systems - Real-Time Innovations announced its partnership with Ansys. This collaboration accelerates the development, testing and deployment of high-performance and high-reliability distributed systems by allowing them to be simulated without their underlying hardware, which may have limited availability or be cost prohibitive.

08:08 EST GreenPower Motor provides update on at-the-market equity offering - GreenPower provided a quarterly update with respect to the Company's at-the-market equity offering program implemented on September 16, 2022 pursuant to a Sales Agreement with Roth Capital Partners. For Q4, GreenPower issued a total of 458,404 common shares through the facilities of Nasdaq at an average share price of $2.40 per share for gross proceeds of $1,100,145. Pursuant to the Sales Agreement, a cash commission of $30,254 was paid to the Agent resulting in net proceeds of $1,069,891.

08:08 EST DatChat board authorizes $2M stock repurchase plan - DatChat announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $2,000,000 of the Company's outstanding common stock, par value $0.0001 per share. Additionally, the Board has approved EF Hutton to be engaged as the broker to implement the Repurchase Plan.

08:07 EST A-Mark Precious Metals purchases minority interest in Texas Precious Metals - A-Mark Precious Metals announced that it has acquired a 12% ownership interest in Texas Precious Metals for cash consideration of $5.04M. Since 2011, TPM has processed over $1.25B in client transactions and has shipped over 100,000 orders to all 50 states. In connection with the acquisition, A-Mark and TPM entered into a four-year extension of their existing exclusive supplier agreement, extending its expiration to January 2027, with automatic two-year renewals. "We are excited to expand our long-standing relationship with TPM with this investment," said A-Mark CEO Greg Roberts. "This transaction reflects our continued efforts to grow our Direct-to-Consumer platform through strategic acquisitions and investments. JM Bullion's CEO, Michael Wittmeyer, and I look forward to partnering with TPM's President and co-founder, Tarek Saab, to leverage our resources and expertise to expand our products and provide other value-added services to the precious metals markets."

08:05 EST Curaleaf receives producer license in Connecticut - Curaleaf Holdings announced that it has received its hybrid producer license from Connecticut's Department of Consumer Protection to supply cannabis to the state's adult-use market, which launches on January 10. Beginning at 10:00 a.m. ET on Tuesday, January 10, consumers over the age of 21 can purchase Curaleaf products in dispensaries approved for adult use sales across the state.

08:04 EST Beam Global receives $500K order from Dallas County - Beam Global announced that it received a $500k order for six EV ARC off-grid EV charging systems from Dallas County, Texas. The systems were purchased using the federal General Services Administration Multiple Award Schedule Contract Number 47QSWA21D0006, which simplifies the federal procurement process, ensures best negotiated pricing, and can be used by many state and local government agencies when the EV ARC systems are intended for EV charging and disaster recovery or preparedness purposes.

08:03 EST SAB Biotherapeutics concludes IND-enabling GLP toxicology study for SAB-142 - SAB Biotherapeutics announced the successful completion of an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic as a way to prevent and/or delay onset and progression of type 1 diabetes and potentially other T-cell mediated autoimmune diseases. The study assessed the toxicity and pharmacodynamic effects of SAB-142 against an FDA-approved T-cell depleting therapeutic at varying doses and found it to be well tolerated and showed a desired dose-dependent pharmacologic effect. SAB will submit the IND filing within approximately 12 months. SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications. Commercially available products for T-cell mediated autoimmune diseases, such as fully-animal antibodies and other monoclonal lymphodepletion therapeutics, require re-dosing and often induce immune-mediated reactions such as serum sickness. As a fully-human polyclonal antibody therapeutic, SAB-142 may be administered multiple times without causing these immune-related adverse reactions, a desired factor when treating life-long diseases such as type 1 diabetes. In the study, SAB-142 was dosed at 1, 5, and 10 mg/kg and commercially available anti-thymocyte globulin was dosed at 5 mg/kg. The study results showed that both SAB-142 and its active control, FDA-approved animal-derived polyclonal anti-thymocyte immunoglobulin, induced transient lymphodepletion confirming the SAB-142 mechanism of action. The dynamics of the depletion appeared to be more prolonged in the cohort with SAB-142 treatment, which could create the opportunity for an optimized dosing regimen.

07:59 EST National Louis University selects BIO-key's PortalGuard IDaaS platform - BIO-key International announced that the National Louis University has selected its PortalGuard IDaaS platform. BIO-key's solution will improve access security to applications, enhance the user experience, and achieve cybersecurity insurance compliance for National Louis, including its primary Chicago and Tampa campuses, with remote access nationwide.

07:58 EST New Gold sees 2022 gold eq. production 325K-365K oz. - Sees 2022 gold production 260K-290K oz. and copper production 25-35 Mlbs.

07:56 EST Moving iMage named global cinema distributor by LEA Professional - Moving iMage Technologies and LEA Professional , a global manufacturer of industry-first, pro-audio amplifiers with cloud- and IoT-based technologies, today announced a partnership to distribute LEA's line of "smart" power amplifiers to the global cinema market. "This partnership brings together two leading, entrepreneurial companies to provide LEA's best-in-class audio technology to the cinema market," said Joe Delgado, executive vice president, sales and marketing. "LEA's line of IoT/Cloud-enabled Professional-grade 'smart' amplifiers and associated technologies are known for reliability, quality and product availability. Combined with MiT's experience in cinema, this partnership presents a significant opportunity for both companies to expand their market opportunity. In addition, this relationship is especially timely given that the global cinema market is in a technology refresh cycle."

07:48 EST Dundee Precious Metals reports Q4 production of 73.4K oz gold, 7.4M lbs. copper - "Our mining operations achieved impressive production results in the fourth quarter, as Ada Tepe delivered its highest quarterly gold production of the year and Chelopech continued its track record of strong performance," said David Rae, President and Chief Executive Officer of Dundee Precious Metals. "2022 was another strong year for DPM, as we delivered robust gold production, advanced our organic growth projects, and ranked in the 91st percentile among mining and metals companies in the 2022 S&P Global Corporate Sustainability Assessment."

07:44 EST Sidus Space selected by Craig Technologies for Navy manufacturing project - Sidus Space announced its selection by Craig Technologies for the manufacturing of 13 Propulsion Plant Team Trainer Maneuvering Area Panels for Bechtel Plant Machinery, or BPMI. Sidus will manufacture, assemble, test, and deliver the Manuevering Panel trainers for Craig Technologies who is leading the design of the Maneuvering Panels for BPMI and with a total project value of over $2M.

07:38 EST Bed Bath & Beyond reports Q3 SSS down 32% - By channel, comparable sales declined 31% in stores and 33% in digital versus the fiscal 2021 third quarter. By banner, comparable sales decreased 34% at Bed Bath & Beyond and declined in the low-twenties at BABY compared to the prior year period.

07:37 EST Bed Bath & Beyond reports liquidity of approximately $0.5B - Reports: Cash Flow from Operations of approximately ($307.6M), Liquidity of approximately $0.5B, including the company's ABL facility and FILO loan less borrowings of $550M.

07:36 EST Priveterra Acquisition, AEON Biopharma announce additional capital commitment - AEON Biopharma and Priveterra Acquisition announced that at least $20 million in additional funding has been committed by existing AEON investors. The commitments have been delivered in connection with the proposed business combination between AEON and Priveterra announced on December 13, 2022, and represent nearly half of the minimum cash requirement for the proposed transaction. The terms of the commitments provide for the issued security to be exchanged or converted into Class A common stock of the combined company upon completion of the proposed transaction, which is subject to the satisfaction or waiver of customary closing conditions and is expected to fund concurrent with or immediately prior to the closing of the proposed business combination.

07:35 EST Nayax announces Nayax Capital - Nayax announced the launch of Nayax Capital, its embedded financing solution for operators looking to purchase a VPOS Touch card reader or Nova Market self-service kiosk to scale their unattended retail operations. Nayax customers can now check out on Nayax's e-commerce shop and receive VPOS Touch or Nova Market solutions using one of Nayax Capital's financing plans, customized for each buyer. Customers will fully own their devices from the start, and will pay for them with 0% APR, no payment schedule, no late penalty, as well as no hidden or additional fees. Nayax customers will make repayments for the devices either via a monthly payment or via a percentage of their sales which will be deducted every billing cycle until the device is fully paid. Nayax Capital is a joint venture between Nayax and Bank Hapoalim, a leading bank in Israel and Alon Feit, formerly the founder of Splitit

07:34 EST Irwin Naturals, Braxia Scientific partner for in-human clinical studies - Irwin Naturals announce it has signed a Letter of Intent entering into a partnership with Braxia Scientific to launch Clinical Research Services across Irwin's U.S. based network of clinics, Emergence.The partnership will bring together Braxia's track record of leadership in mental health treatments and current comprehensive clinical research capabilities to 12 Emergence clinics in 5 US states. Under the terms of the LOI, Irwin will invest up to $2M over the next 12 months to launch initial clinical research services beginning with at least 5 clinics in Florida. Irwin and Braxia's partnership will create a mental health focused clinical research platform designed to streamline and accelerate the process of in-human clinical development of new therapies, including seamless patient recruitment through to FDA application. The partnership will support multiple large and small pharmaceutical sponsors, innovative biotechnology companies, medical device companies, government and non-governmental institutions who seek to carry out the development of new therapies in the area of mental health in the US. The partnership is subject to execution of a final definitive legal agreement covering the above and other material terms of the relationship between Braxia and Irwin.

07:33 EST Palatin's PL8177 shows therapeutic effect in arthritis pre-clinical study - Palatin announced Frontiers in Immunology published a manuscript summarizing data demonstrating PL8177 provides therapeutic effects in inflammatory conditions, including arthritis. Palatin, in collaboration with The William Harvey Research Institute, Queen Mary University of London, in London, UK, conducted the study to assess the immunopharmacology of a PL8177 in vitro and in a mouse model of inflammatory arthritis. Key findings included PL8177 activation of mouse and human MC1 receptors and that PL8177 displayed pro-resolving activity and counteracted the inflammatory profile of zymosan-stimulated macrophages, reducing the release of IL-1beta, IL-6, TNF-alpha and CCL-2. In the context of joint inflammation, PL8177 reduced the clinical score, paw swelling and incidence of severe disease as well as the recruitment of immune cells into the arthritic joint. Melanocortins have anti-inflammatory and pro-resolving effects. Palatin has multiple MC1r agonist candidates in pre-clinical and clinical development. Palatin is conducting a Phase 2 multi-center, randomized, double-blind, placebo-controlled, adaptive design, clinical study of PL8177, with once daily oral dosing in adult UC subjects. The PL8177-205 interim assessment is expected to occur in 1Q23, with final topline data anticipated in 2Q23.

07:32 EST PyroGenesis signs $6M contract with advanced materials firm - PyroGenesis Canada announces that, further to the press release dated September 13, 2022, the Company has received the final signed contract to provide the Company's SPARC refrigerant waste destruction system to an advanced materials company. The system is the first of two systems that the Client has indicated they may require. This first system is contracted at approximately $6MM, not including ongoing after-sales support of an indeterminate amount. This contract includes a first payment of approx. $2.2MM. The first payment has been received. PyroGenesis has been contracted to design and build the SPARC refrigerant waste destruction system. PyroGenesis will also supervise and support contractors in the system installation within a new facility being built by the Client. The project has an approximate production-to-delivery timeline of 18 months. "PyroGenesis continues to be recognized for its fossil-free waste destruction systems, in jurisdictions where tightened hazardous waste disposal regulations combined with cost-offsetting carbon credits are resulting in a need for a safer destruction of various hydrocarbons, including refrigerant chlorofluorocarbons," said Mr. P. Peter Pascali, CEO and Chair of PyroGenesis. "This contract is for a land-based SPARCTM system which comes on the heels of the recent announcement of the first deployment for the USS Gerald R. Ford aircraft carrier - the world's most technologically advanced ship - which set sail with PyroGenesis' ship-board PAWDS waste destruction system installed. The PAWDS system is, interestingly, the technology platform used for SPAR."

07:23 EST Dish's Wireless Chief Commercial Officer Stephen Bye joins Board of Directors - Dish has named Stephen Bye to its Board of Directors, effective January 18. Since 2019, he has served as the Dish Wireless Chief Commercial Officer supporting the development and commercialization of the company's standalone 5G network. He will step down from his role as Chief Commercial Officer at Dish Wireless on January 17 and assume the role of President of the Connectivity division at Ziff Davis (ZD).

07:19 EST Amarin expects cash to support continued operations - Amarin reiterates its belief that current cash and investments and other assets are adequate to support continued operations, including European launch activities.

07:18 EST BioNTech enters agreement to acquire InstaDeep for GBP 362M in cash - BioNTech and InstaDeep announced that they have entered into an agreement under which BioNTech will acquire InstaDeep. The transaction includes a total upfront consideration of approximately GBP 362M in cash and BioNTech shares to acquire 100% of the remaining InstaDeep shares, excluding the shares already owned by BioNTech. In addition, InstaDeep shareholders will be eligible to receive additional performance-based future milestone payments up to approximately GBP 200M. The transaction follows BioNTech's initial equity investment as part of InstaDeep's Series B financing round in January 2022. The acquisition supports BioNTech's strategy to build world-leading capabilities in AI-driven drug discovery and development of next-generation immunotherapies and vaccines to address diseases with high unmet medical need. The transaction will combine two organizations with a common culture and is expected to add approximately 240 highly skilled professionals to BioNTech's workforce, including teams in AI, ML, bioengineering, data science, and software development. Through the acquisition, BioNTech will grow its network of global research collaborators in the field and expand its footprint in key talent hubs across the United States, Europe, Africa and the Middle East. "Since the inception of BioNTech, we have focused on leveraging computational solutions to create personalized immunotherapies that can reach a wide patient population," said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "The acquisition of InstaDeep allows us to incorporate the rapidly evolving AI capabilities of the digital world into our technologies, research, drug discovery, manufacturing, and deployment processes. Our aim is to make BioNTech a technology company where AI is seamlessly integrated into all aspects of our work." The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory approvals. Upon closing, InstaDeep will operate as a UK-based global subsidiary of BioNTech.

07:14 EST Veeva issues statement in support of proposed FTC ban on non-competes - Veeva Systems announced its support for the proposed Federal Trade Commission - FTC - rule to ban employee non-competes. Veeva stated, "For more than a decade, Veeva has worked against the use of non-compete agreements and fought to have them banned nationally. The company has never asked Veeva employees to sign non-compete agreements as a condition of employment and doesn't let an existing non-compete agreement stop it from hiring a qualified candidate. Veeva provides legal defense to employees sued by former employers trying to enforce this abusive and outdated practice. The company strongly supports intellectual property rights, which are protected through confidentiality agreements and trade secret laws. Non-competes are not necessary for IP protection and only serve to limit employee mobility". CEO Peter Gassner stated on the proposed FTC rule to ban non-competes: "The swift action to ban non-competes is an important step in advancing employee freedom, innovation, and the economy. People have a fundamental right to make their own career choices. These decisions impact their livelihoods and professional growth and should not be dictated by lawyers and corporations. This is about trusting employees. No one is motivated to do their best work under a cloud of threats or when locked into a job. The mobility of talent has created the most innovative companies in the world. Banning non-competes is good for business, innovation, and economic growth."

07:13 EST Amarin appoints Stewart to board of directors - Amarin (AMRN) announced that Murray Stewart, D.M., F.R.C.P., has been appointed to the Company's Board of Directors. Following the appointment of Dr. Stewart, the Amarin Board will be made up of approximately 70 percent of new independent directors who were named to the Board over the last 12 months. Dr. Stewart is a physician by training and brings more than 30 years of cardiometabolic academic and industry experience to the Amarin Board of Directors. Recently, Dr. Stewart was Chief Medical Officer at Rhythm Pharmaceuticals (RYTM).

07:12 EST Sernova, Evotec on track to clinically test iPSC-derived islets in Cell Pouch - Sernova (SEOVF) announced that significant progress has been achieved in its collaboration with Evotec SE (EVO). This progress includes advancement of Evotec's iPSC derived islet-like clusters in combination with Sernova's implantable Cell Pouch device toward a first-in-human Phase 1/2 clinical trial for the treatment of patients with T1D and severe hypoglycemia slated for regulatory filing in 2024. The objective of the collaboration is to produce an off-the-shelf, commercially viable, ethically derived cell therapy treatment for people suffering from T1D. The treatment would include Sernova's Cell Pouch System incorporating Evotec's iPSC-derived islet-like clusters. The combination product is anticipated to be the first treatment of its kind to reach clinical testing for T1D. The Evotec and Sernova collaboration has to date resulted in the following significant achievements: Development of a robust, cost-efficient, scalable, highly controlled iPSC differentiation protocol with the ability to cryopreserve and store batches of differentiated islet-cell clusters; Demonstration of excellent islet-like cluster survival under standard shipping conditions and following transplantation; Demonstration of consistent long-term insulin independence with no hypoglycemic events and consistent safety profiles in a gold standard T1D preclinical model with Evotec's iPSC-derived islet-like clusters transplanted in Sernova's Cell Pouch; iPSC islet-like cluster manufacturing scale-up and technology transfer activities to Evotec's iPSC GMP facility are well under way in preparation for manufacture of clinical and commercial iPSC islet-like clusters supply; Interactions with experts in support of design of the first Phase 1/2 clinical trial. Based on these achievements the following activities will be continuing throughout 2023 in preparation for regulatory filings anticipated in 2024: Completion of standard formal safety/toxicology studies and other required preclinical studies; Identification and securing of potential clinical study sites to enable efficient patient enrollment following initiation of the Phase 1/2 clinical study; Preparation of regulatory submissions for planned trial geographies, combining both the established library of regulatory documentation for Sernova's Cell Pouch and that developed by Evotec for their iPSC islet-like clusters

07:09 EST Wayfair Professional launches year-long partnership with Lamb & Co. - Wayfair that its business program, Wayfair Professional, is entering into a year-long brand partnership with Lyndsay Lamb and Leslie Davis of Lamb & Co. This integrated partnership aims to showcase how Lamb and Davis utilize Wayfair Professional to power their business, renovations, and design work for Lamb & Co. The twin sisters, who are best known for co-hosting HGTV's "Unsellable Houses," are also multi-business entrepreneurs, and top-producing real estate agents with a passion for home design, renovation, and staging. 2022 Tastemaker Winner, Defining Space + Style. "As entrepreneurs, we love to partner with other businesses that strive to serve each customer with care. That's why we're so excited to work with Wayfair Professional throughout 2023 and highlight the many benefits that designers, renovators, and other Pros have access to through their free business program," says Lamb on the collaboration.

07:08 EST Aura Minerals reports Q4 production of 67,663 GEO - Aura Minerals announced preliminary production results from the Company's three operating mines for the fourth quarter of 2022. Total production reached 67,663 gold equivalent ounces during Q4 2022. Excluding Gold Road, it was the second highest production achieved in a single quarter, behind its Q4 2021 production. Total production for 2022 reached 242,524 GEO at current prices - also the second highest production in a single year in the history of the Company. Total production in GEO increased 16% in Q4 2022 compared to Q3 2022, when calculated based on current prices. Based on constant prices, production in Q4 2022 was 5% lower than in Q4 2021, when Aura recorded its highest quarterly production in its history. At EPP, production in GEO increased by 50% compared to Q3 2022 and by 56% compared to Q4 2021 as operations accessed phase II of the Ernesto pit, resulting in higher grades. This was the highest quarterly production at EPP in the history of the Company. At Aranzazu, production in GEO increased by 9% relative to Q3 2022 as a result of high tonnage processe and increase in gold and copper grades due to mine sequencing. At San Andres production in GEO was 13% lower than in the previous quarter. Lower production in Q4 2022 was due to longer than expected leaching cycle during the quarter; however, ore mined increased 44% compared to the previous quarter. Due to the leaching cycle, an estimated additional 1,600 Oz were produced and not sold during the quarter and are in the circuit by year end and expected to be recovered and sold in early 2023. Therefore, production at San Andres is expected to increase in Q1 2023 once the leaching process of the ore fed during Q4 2022 is completed and gold is recovered at the mill. Rodrigo Barbosa, the Company's President and CEO comments, "Last quarter we had the second highest production in Aura's history, which demonstrates consistency in our growth plans. In addition, during the quarter we advanced Almas's construction, finishing the year with 87% of the construction completed and on track to deliver the project early this year. The end of 2022 was an important quarter as we made progress on our understanding of the Borborema project and updated our guidance to achieve 400,000 GEO (annualized) in 2024 and 450,000 GEO in 2025, while paying US$20 million in dividends and US$10 million in share buybacks resulting in total yield of about 6% in 2022 only. We are now set up for an even stronger 2023 with a continued focus on growth while returning capital to our shareholders."

07:07 EST Plug Power to deliver two 30 TPD hydrogen liquefaction systems to TC Energy - Plug Power (PLUG) has been awarded an order to deliver two 30-tons-per-day, TPD, hydrogen liquefaction systems to TC Energy Corporation (TRP). These 30TPD hydrogen liquefaction systems utilize a hydrogen refrigeration cycle and bring to market one of the most energy efficient designs to date. Through the acquisition of Joule Processing LLC in 2022, Plug gained core competency in liquefaction systems known for their operational efficiency, flexibility and reliability. Plug's hydrogen liquefaction system has one of the most energy-efficient designs on the market utilizing hydrogen as the refrigerant in the main liquefaction cycle. "As a global leader in manufacturing reliable hydrogen liquefiers, Plug is focused on optimizing both capital and operational efficiency for our customers at every stage of the hydrogen value chain," said Andy Marsh, CEO of Plug. "This deal validates our investment in Plug's liquefaction capabilities as part of our vision to build an end-to-end green hydrogen solution. We share TC Energy's commitment to providing sustainable and secure energy, and together we look forward to accelerating the growth of the hydrogen market."

07:05 EST Arko Corp. announces CFO Bassell to retire - ARKO announced that Chief Financial Officer, CFO, Don Bassell has informed the Company of his intent to retire by the end of 2023, after 42 years in the industry. Bassell is expected to remain as Chief Financial Officer until his successor is in place and remain with the Company until approximately April 2024 to assist with the transition process and ensure continuity of operations. The Company plans to promptly commence a process to identify a successor, considering both internal and external candidates.

07:04 EST Builders FirstSource announces Rush named as Chief Executive Officer - Builders FirstSource announced that Dave Rush has been named Chief Executive Officer, effective immediately. Rush has served as Interim Chief Executive Officer of Builders FirstSource since November 18, 2022, when he was also appointed to the Company's Board of Directors.

07:03 EST Kymera Therapeutics shares key 2023 goals - Kymera Therapeutics announced its research, development and corporate goals for 2023. Nello Mainolfi, PhD, Founder, President and CEO said, "Kymera ended 2022 with a cash balance of approximately $560 million, providing the company with an anticipated cash runway into the second half of 2025 that is expected to take us past the proof-of-concept Phase 2 data for KT-474, as well as early proof-of-concept data for KT-413, KT-333 and KT-253." Continued Dr. Mainolfi. "In addition, we are well-positioned to advance our wholly-owned clinical programs while continuing significant investments in our platform and robust discovery pipeline, additional details about which we look forward to sharing in 2023." Kymera's 2023 Objectives: Key objectives include: Collaborate with Sanofi to Initiate KT-474 Phase 2 trials; Publish results of KT-474 Phase 1 trial, including the HS/AD patient cohort; Demonstrate KT-413 clinical anti-tumor activity in target patient populations; Demonstrate KT-333 clinical anti-tumor activity in target patient populations; Initiate KT-253 Phase 1 trial in solid and hematological tumors and demonstrate KT-253 clinical proof-of-mechanism in patients; Deliver at least 2 new development candidates/Investigational New Drugs from the preclinical pipeline in areas of large clinical and commercial opportunity and pathways where TPD has potential to provide either the only or the best-in-class solution; Further expand the capabilities of Kymera's Pegasu platform and continue to leverage ; Kymera's E3 Ligase Whole-Body Atlas of over 600 unique E3 ligases, with a focus on tissue restricted E3 ligases; Expand novel molecular glue franchise in areas of unmet medical need, exploiting a newly identified degron motif; Advance existing collaborations, or execute additional strategic partnerships, that support the company's evolution into a fully integrated, global biopharmaceutical company

06:58 EST Coinbase to cut workforce by about 950 employees in further restructuring - In a regulatory filing, Coinbase reported that on January 10, the company announced a further restructuring plan to manage its operating expenses in response to the ongoing market conditions impacting the cryptoeconomy, as well as ongoing business prioritization efforts. The plan involves a reduction of the company's workforce by approximately 950 employees. The company expects execution of the plan to be substantially complete by the second quarter of 2023. In connection with these actions, the company estimates that it will incur approximately $149M to $163M in total restructuring expenses, consisting of approximately $58M to $68M in cash charges related to employee severance and other termination benefits. Of the aggregate charges that the company expects to incur in connection with the plan, the company expects that approximately $91M to $95M will be in stock-based compensation expenditures relating to the acceleration of the vesting of outstanding equity awards in accordance with the terms of such awards. The company expects to recognize substantially all of these charges in the first quarter of 2023. "The estimates of the charges and expenditures that the company expects to incur in connection with the plan, and the timing thereof, are subject to a number of assumptions, including local law and consultation requirements in various jurisdictions, and actual amounts may differ materially from estimates. The company may also incur charges and expenditures not currently contemplated due to unanticipated events that may occur in connection with the plan," the filing stated.

06:55 EST Endeavour Silver reports 2022 production 9.0M silver eq. oz. - Endeavour Silver reported 2022 production of 5,963,445 silver oz. and 37,548 gold oz, for silver equivalent production of 9.0M oz. Q4 production was 1,830,835 silver oz and 10,370 gold oz, for silver equivalent production of 2.7M oz. 2022 full year production exceeded the upper range of its guidance of 7.6M-8.0M oz AgEq due to continuing strong performance at Guanacevi. Annual silver and gold production exceeded the upper range of guidance by 17% and 4% respectively. Financial due diligence continues on financing the Terronera project: The company intends to make a formal construction decision subject to completion of a financing package and receipt of additional amended permits in the coming months. "We are very pleased to have exceeded the top end of the 2022 production guidance, with full year silver equivalent production improving by 9% year over year and fourth quarter silver equivalent production up 21% over the prior year period. Q4 throughput and grades at Guanacevi exceeded plan, contributing to the significant out-performance of the Guanacevi operations during 2022," stated CEO Dan Dickson.

06:44 EST CECO Environmental expects Q4 orders to exceed $145M - CECO Environmental announced it expects orders for the fourth quarter to exceed $145M, an increase of at least $55M, or 60%, over the prior-year quarter and $43M, or 42%, on a sequential basis, providing CECO with year-end backlog at or near record levels.

06:21 EST Intel selects Encompass for computer technology components - Intel and Encompass Supply Chain Solutions, a provider of replacement parts and supply chain services for a range of product brands, have finalized an agreement for Encompass to manage NUC parts for Intel. Under the deal, Encompass will serve as a master distributor of components used for the repair of Intel NUC personal computers. NUC - Next Unit of Computing - is a small form factor device or compute element, which contains everything a standard PC does: processor, memory, SSD, LAN or WiFi, as well as support for integrated and discrete graphics options.

06:03 EST Energous, SATO Holdings announce partnership - Energous and SATO Holdings announced a partnership to develop joint solutions that combine Energous' 1W WattUp PowerBridge transmitters with IoT solutions for next-generation smart store applications. Through this joint development, the two aim to realize wireless powering of Wiliot IoT Pixel sensor tags from a distance of 5m to a maximum of 10m for asset management and inventory management solutions in stores and warehouses that SATO is building.

05:15 EST Virgin Orbit says first orbital launch fell short of target - The company said, "The historic first attempt to launch satellites from British soil reached space late last night, but ultimately fell short of reaching its target orbit. After successfully taking off from the runway at Spaceport Cornwall - which just a few weeks ago was transformed from a mere slab of empty cement at a commercial airport to the world's newest space launch operations center - and travelling to the designated drop zone, Cosmic Girl, the customized 747 that serves as the LauncherOne system's carrier aircraft, successfully released the rocket. The rocket then ignited its engines, quickly going hypersonic and successfully reaching space. The flight then continued through successful stage separation and ignition of the second stage. However, at some point during the firing of the rocket's second stage engine and with the rocket travelling at a speed of more than 11,000 miles per hour, the system experienced an anomaly, ending the mission prematurely. Though the mission did not achieve its final orbit, by reaching space and achieving numerous significant first-time achievements, it represents an important step forward. The effort behind the flight brought together new partnerships and integrated collaboration from a wide range of partners, including the UK Space Agency, the Royal Air Force, the Civil Aviation Authority, the US Federal Aviation Administration, the National Reconnaissance Office, and more, and demonstrated that space launch is achievable from UK soil. Out of five LauncherOne missions carrying payloads for private companies and governmental agencies, this is the first to fall short of delivering its payloads to their precise target orbit."

05:09 EST Elbit Systems awarded $180M contract from IMoD - Elbit Systems announced that it was awarded a contract in an amount of approximately $180M from the Israeli Ministry of Defense, or IMoD, to provide, operate and maintain the new Mission Training Center, or MTC, for the Israeli Air Force's, or IAF, F-16 fleet. The contract will be delivered over a three-year period with an additional fifteen year period that will include operation and maintenance services.